rss 4 medicine
bringing rss to the medical world
Want more? Visit www.medworm.com - the RSS search engine for medics - medical headlines from over 1500 handpicked rss feeds


Pharma Industry / Biotech Industry News From Medical News Today

Latest Health News and Medical News posted throughout the day, every day.

UC San Diego To Lead New Pharmacogenomics Project 8 Sep 2010

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Cuts To Public Spending On Research Will Jeopardise Funding For Medical Research From Private And Charitable Sources, UK 8 Sep 2010

The Academy of Medical Sciences has warned that the UK's competitive advantage in medical science is reliant on a Government commitment to maintaining a thriving publicly funded research base. Any cuts risk damaging the UK's rich landscape of medical research funders and would jeopardise the private and charitable funding leveraged by public spending...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Court Denies Sandoz/Momenta's Summary Judgment Of Invalidity In Copaxone(R) Litigation 8 Sep 2010

Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. District Court for the Southern District of New York has denied a motion for summary judgment filed by Sandoz Inc./Momenta Pharmaceuticals, Inc., that the patents at issue are invalid for indefiniteness. The court has not yet set a trial date...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


The Benefits Of Hormone Replacement Therapy Overstated And Harms Downplayed By Ghostwritten Articles 8 Sep 2010

The first academic analysis of the 1500 documents unsealed in recent litigation against the pharmaceutical giant Wyeth (now part of Pfizer) reveals unprecedented insights into how pharmaceutical companies use ghostwriters to insert marketing messages into articles published in medical journals. Dr...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


4th Annual Biomarker Discovery And Development Conference, San Francisco, CA Oct. 20-22, 2010 8 Sep 2010

The 4th Annual Biomarker Discovery and Development Conference features presentations of novel technologies to discover biomarkers, how they are utilized to streamline the development process by reducing time and costs and minimize drug attrition associated with safety concerns, and highlight their utility in clinical trials and as companion diagnostics in the clinics...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Children's Hospital Boston And Particle Sciences Cooperate On Translational Medicine Efforts 8 Sep 2010

Particle Sciences Inc. (PSI), a leading pharmaceutical Contract Research Organization (CRO), has been engaged by Children's Hospital Boston to help advance early stage molecules and drug innovations into new therapeutic products for patient care...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


TenX Biopharma Reinitiates Enrollment In Pivotal Phase III, CTCL Trial 8 Sep 2010

TenX Biopharma, Inc. announced that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients. The trial enrollment was suspended in October 2008 while Genmab (CO:GEN) was seeking a out-license agreement to further develop the compound...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


To Reach, Perchance To Kill The Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That 'Sea Of Troubles' 8 Sep 2010

Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


BIO India International Partnering Conference Showcases Vibrant And Growing Indian Biotech Industry To Global Leaders 8 Sep 2010

The Biotechnology Industry Organization (BIO) will be hosting the first-ever BIO India International Partnering Conference in Hyderabad, India on September 21-22. BIO India will bring together biotechnology and pharmaceutical companies from North America, Europe and Asia to meet and explore business opportunities with India's emerging biotech sector...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


INL Selects Vistec's Electron-Beam Lithography System EBPG5200 For Nanotechnology Research 7 Sep 2010

Vistec Lithography, a leading supplier of advanced electron-beam lithography systems has announced today that the International Iberian Nanotechnology Laboratory (INL) in Braga, Portugal has placed an order for Vistec's electron-beam lithography system EBPG5200...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Hans-Joachim Bohm, Mathai Mammen, Tom Novak And Others To Present At 6th Modern Drug Discovery And Development Summit, Oct 20-22, San Francisco 7 Sep 2010

The at 6th Modern Drug Discovery and Development Summit will feature plenary keynote presentations from Mathai Mammen, Senior Vice President of Research and Early Clinical Development at Theravance; Gilles J. A. Gallant, Vice-President of Clinical Oncology at Human Genome Sciences; Tom Novak, Ph.D,Senior Vice President of Research & Development, Fate Therapeutics; and Hans-Joachim Bohm, Ph.D...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Stephen Turner And Michael R. Jackson To Present At Assay And Drug Discovery Technologies Conference, San Diego, Sept. 20-21, 2010 7 Sep 2010

Stephen Turner, Founder & Chief Technology Officer of Pacific Biosciences and Michael R. Jackson, Vice President, Drug Discovery and Development of Burnham Medical Research Institute will give a keynote presentation at the 5th Assay and Drug Discovery Technologies Conference to be held this year in San Diego, CA Sept. 20-21, 2010 by GTCbio...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Urgent Action Needed To Ensure UK Patients Get Their Medicines, UK 7 Sep 2010

Urgent action is needed to tackle the worsening problems UK patients are facing when trying to receive their medicine prescriptions...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Key To Slowing Rise Of Antibiotic-Resistant Infections Is Pharmaceutical Conservation 7 Sep 2010

The United States must focus on conserving the use of antibacterial drugs, or face a public health crisis from rapidly rising rates of antibiotic-resistant infections, according to an analysis just released...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


European Medicines Agency Holds First Scientific Workshop On Nanomedicines 7 Sep 2010

On 2-3 September 2010, the European Medicines Agency (EMA) hosted the first international scientific workshop on nanomedicines. Some 200 European and international participants from 27 countries including Australia, Canada, India, Japan and the United States discussed benefits and challenges arising from the application of nanotechnologies to medicines...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


ThromboGenics Presents Positive Pooled Results From The MIVI-TRUST Phase III Program 7 Sep 2010

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


LEVITRA 10mg Orodispersible Tablet For The Treatment Of Erectile Dysfunction Approved In Europe 7 Sep 2010

The European Commission has approved a new formulation of Levitra® (vardenafil HCI). Levitra 10mg orodispersible tablet will be the first erectile dysfunction (ED) medication available in this novel and convenient formulation...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Novartis And Collaborators Discover Novel Antimalarial Drug Candidate 7 Sep 2010

Novartis announced that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Concern About Rosiglitazone (Avandia) And How Drugs Are Regulated And Promoted, BMJ 6 Sep 2010

There is serious concern about top-selling diabetes drug rosiglitazone (Avandia), its safety, as well as the whole system by which medications are regulated, evaluated and promoted worldwide, according to a BMJ (British Medical Journal) investigation. Dr. Fiona Godlee, BMJ Editor-in-Chief, thinks Avandia should not have been licensed; she believes it should be withdrawn...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Compliance And Concordance: Good For Patients And For Pharma - October 19-20, Philadelphia 6 Sep 2010

Peter Mansell explores how effective concordance can take the strain off industry-patient group partnerships. Pharmaceutical companies and patient organizations are never going to be the easiest of fits. It is not so much due to any fundamental unwillingness to work together, or lack of common ground, but rather to the kind of attention these relationships inevitably attract...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Almost Half Of All Americans Use Prescription Drugs Each Month 6 Sep 2010

Nearly half of all Americans used at least one prescription drug per month in 2008, according to a study by the Centers for Disease Control and Prevention, Bloomberg reports. That's a 10 percent increase over the preceding decade. Over that time, yearly spending by Americans on drugs doubled to $234 billion. "The two biggest-sellers last year were Pfizer Inc...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


European Commission Issues Positive Decision For Approval Of Seroquel XR As An Add-On Treatment Of Major Depressive Disorder 5 Sep 2010

AstraZeneca announced that the European Commission (EC) has issued a positive decision for the approval of once-daily SEROQUEL XR (quetiapine fumarate) Extended Release Tablets as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Merck's Cladribine Tablets For Multiple Sclerosis Approved In Australia 5 Sep 2010

Merck KGaA announced that the Australian Therapeutic Goods Administration (TGA) has approved Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS)(1). Cladribine Tablets will be registered in Australia under the trade name Movectro®...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Forecasting: Patient Flow Modeling Comes Of Age - Pre-Summit Workshop October 5th Boston 4 Sep 2010

Judith Kulich, Associate Principal, and Emily Jin, Manager, at ZS Associates talk to eyeforpharma about how patient flow modeling can inform forecasting. Patient flow, or system dynamics forecasting is a common approach for modeling situations in which patient potential is affected by movement between disease states...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


Medical Affairs Report Outlines Resource Needs For Group Success 4 Sep 2010

The Medical Affairs function arguably plays the most critical role in a biopharmaceutical organization, with heavy responsibilities across areas such as clinical development, scientific publications, KOL development, and medical education. These areas must operate effectively for new products to succeed...

Bookmark article in → Del.icio.us | Digg | Furl | My Web 2.0 | Newsvine | Reddit | Spurl | Search Technorati


unique visitor counter

home - news - rss readers - rss writers - directory - forum - contact us